Tag - PTI-428

Proteostasis Therapeutics (NASDAQ: PTI) dosed the first patient in a 28-day Phase 2 trial evaluating combinations of PTI-801, PTI-808 and PTI-428 for the treatment of cystic fibrosis (CF). CF is caused by a mutation in...